Biomarkers can be categorised from type 0 (genotype or phenotype), through 6 (clinical scales), each level representing a part of the processes involved in the biological system and drug treatment. This classification facilitates the identification and connection of information required to fully (mathematically) model a disease and its treatment using integrated information from biomarkers. Two recent reviews thoroughly discussed the current status and development of biomarkers for epilepsy, but a path towards the integration of such biomarkers for the personalisation of anti-epileptic drug treatment is lacking. Here we aim to 1) briefly categorise the available epilepsy biomarkers and identify gaps, and 2) provide a modelling perspective on approaches to fill such gaps. There is mainly a lack of biomarker types 2 (target occupancy) and 3 (target activation). Current literature typically focuses on qualitative biomarkers for diagnosis and prediction of treatment response or failure, leaving a need for biomarkers that help to quantitatively understand the overall system to explain and predict differences in disease and treatment outcome. Due to the complexity of epilepsy, filling the biomarker gaps will require collaboration and expertise from the fields of systems biology and systems pharmacology.
Introduction
A large unmet medical need exists for the 50 million people with epilepsy worldwide, as up to 30% of them are not satisfactorily treated (Ngugi et al., 2010; Sillanpää and Schmidt, 2006) . A major cause of dissatisfactory anti-epileptic drug (AED) treatment outcome is large inter-and intra-individual variability in pharmacokinetics (PK), pharmacodynamics (PD), and pathophysiology (van Dijkman et al., 2016) . To better understand and explain such variability, biomarkers are needed. For epilepsy, biomarkers have been defined as "an objectively measurable characteristic of a biological process that reliably identifies the development, presence, severity, progression, or localization of an epileptogenic abnormality" which would suggest only a minor focus on the biological features of a treatment effect (Pitkänen and Engel, 2014) . Two recent reviews provided an overview of the available epilepsy biomarkers (Pitkänen et al., 2016; Walker et al., 2016) . Pitkänen et al. stated that "Biomarker discovery could be regarded as an advance in the personalisation of medicine, and could allow prevention in the right person at the right time, rather than just symptomatic treatment". However, biomarker data alone will not automatically lead to personalised medicine. PK, PD and disease models, in conjunction with individual patient data, are required to estimate patient-specific parameters and make subsequent treatment choices (Knibbe and Danhof, 2011; Standing, 2016) . Furthermore, the use of biomarkers can result in a more effective and structured drug development process (Cohen et al., 2015) .
A classification system exists that categorises biomarkers with regard to their place in modelling PK, PD and disease processes (Danhof et al., 2005) , in terms of cascading types; type 0 (genotype or phenotype), type 1 (drug concentration), type 2 (target occupancy), type 3 (target activation), type 4 (physiological response), type 5 (pathophysiological response), and type 6 (clinical scales). Each type represents part of the interactions between (patho-) physiology and treatment, which, if adequately described, would allow for the prediction of in vivo drug effect based on intermediary biomarkers (Fig. 1.) . Categorisation of the available epilepsy biomarkers according to this system may aid in the identification of biomarker gaps, and help to determine a way forward in the use of epilepsy biomarkers for personalised medicine and drug development. The aims of this review are therefore to 1) briefly categorise the available epilepsy biomarkers and identify gaps, and 2) provide a modelling perspective on approaches to fill such gaps. oping epileptic seizures or alter the chance of responding to drug therapy (Rossignol et al., 2014; Myers and Mefford, 2015; Pitkänen et al., 2016; Walker et al., 2016) . These include the genes that encode for Na + channels, Ca 2 + channels, K + channels, and the nicotineacetyl-choline-and GABA A receptors. Some examples of such genetic markers are genetic differences in serotonergic transmission related to the occurrence of temporal lobe epilepsy and epileptogenesis following traumatic brain injury with subsequent changes in GABAergic expression. Epileptic seizures are based on excessive synchronised neuronal excitations, and thus it comes to no surprise that genes related to either increased excitation or decreased inhibition are implicated in seizure susceptibility. Neuro-inflammation is considered an important factor in epileptogenesis after traumatic brain injury or stroke. Genetic markers for CD40, a costimulatory protein found on antigen presenting cells that is required for their activation, interleukins, and oxidative stress seem to support this. Most likely these genes are not single contributors to risk, but part of a large network of interacting genes, some innocuous on their own, and other factors eventually leading to epileptogenesis. MicroRNA, or miRNA, are small non-coding RNA molecules involved in post-transcriptional gene regulation and gene silencing. Some of these miRNA circulate through the body and thereby provide a bridge between genetic expression, either normal expression of mutated genes, or abnormal expression of otherwise normal genes, and clinical presentation. Two miRNAs, hsa-miR-487a and hsa-miR-9a-3p, have been found to correlate to neuro-inflammation and epileptogenesis, which perhaps one day could allow clinicians to determine if immunosuppression for the prevention of epileptogenesis is indicated in their patient (Zucchini et al., 2014; Roncon et al., 2015) . The miRNA hsamiR-106b-5p, part of an miRNA family implicated in cell proliferation, was found to diagnose idiopathic generalised epilepsy at a sensitivity and specificity of 80% and 81% respectively (Wang et al., 2015) .
Available Biomarkers

Type 1 -Drug Concentration
For infectious diseases, therapeutic drug monitoring (TDM) of antibiotic plasma concentrations is commonly used to assure sufficient drug exposure; plasma concentrations are considered representative for the antibiotic target site. In AED therapy, plasma AED concentrations are theoretically simple biomarkers, yet much controversy exists regarding its use in clinical practice. Objections to plasma PK optimisation of AED therapy include the lack of a clear correlation between plasma concentrations and AED therapy outcome in the individual patient in the clinic, the burden on the patient, and the cost of sampling. While target site exposure is undeniably the main driving force behind efficacy, pharmacokinetic variability obscures the correlation between dose, plasma concentration and target site concentration, and thereby efficacy. Yet, plasma exposure has been shown to correlate to efficacy for a number of AEDs (Nakashima et al., 2015; Ogusu et al., 2014; Delattre et al., 2012; Van Den Broek et al., 2012; Girgis et al., 2010) , suggesting that clinical titration to a certain efficacious level of systemic exposure may still be optimised by TDM (van Dijkman et al., 2017b) , especially in the face of polytherapy (van Dijkman et al., 2017a) .
Few studies have investigated the correlation between plasma and cerebrospinal fluid (CSF) or target site AED concentrations in humans. In 22 pharmacoresistant patients undergoing epileptic focus resection, large differences in AED concentrations were found between plasma, medial temporal gyrus dialysate, and excised tissue (Rambeck et al., 2006) . However, plasma and CSF concentrations of topiramate were highly correlated in a group of 14 regular, non-pharmacoresistant patients (Christensen et al., 2001 ). Finally, one study showed parallel profiles of valproic acid concentrations in plasma, CSF, and extracellular fluid (ECF), albeit not at the same concentration level (Lindberger et al., 2001) . These three studies suggest that regular patients' AED concentrations in CSF, and possibly at the target site, can be seen as a simple ratio of plasma concentrations, whereas CSF concentrations in non-responding patients may not show the same correlation, requiring more elaborate methods for determining target site exposure. For the moment, evidence is too limited for it to be used in clinical decision making, or in drug development to determine the source of inadequate response.
As an alternative to CSF sampling, total or local brain AED concentrations could be measured by positron emission tomography (PET) (Kim et al., 2010; Syvänen et al., 2013) . Such an intensive PK analysis and optimisation is not indicated in the patient that responds well to initial drug titration, but may still be indicated for refractory or non-responding patients to differentiate between failure to reach adequate target site exposure and failure to respond pharmacodynamically. Inadequate target site exposure could be adjusted for by dose adjustments or blood-brain barrier (BBB) manipulation, for example by Pgp inhibition (Clinckers et al., 2005) , whereas pharmacodynamic failure would require switching to another AED or add-on therapy. Although an intensive PK workup (i.e. determining an individual's systemic, and possibly cerebral concentrations) incurs extra costs and burden, it should be offset against the costs of hospital admissions, missed work days, and other adverse results from seizures or severe side effects in non-responding patients. In well-responding patients, it is still highly recommended to measure drug plasma concentrations, to be able to differentiate between inadequate exposure due to changes in PK, the development of pharmacoresistance, or non-compliance in patients that becomes treatment resistant at a later time (Patsalos et al., 2008) . Some of the burden of plasma sampling may be preventable by substituting it with the newer, lesser invasive techniques like dried blood spot and saliva sampling, which have seen some increased interest in recent years (Milosheska et al., 2015; Patsalos and Berry, 2013) , but would add another source of variability to the analysis.
Type 2 -Target Occupancy & Type 3 -Target Activation
Target occupancy is a major determinant in drug efficacy, but few suitable biomarkers are available. In vitro binding kinetics, investigated for many AEDs, are not directly translatable to in vivo. PET occupancy studies can be performed to investigate target occupancy in vivo, but it requires at least 12 research subjects, and two PET scans per individual (Zhang and Fox, 2012) , making it impractical for AED therapy personalisation in the clinic and very costly for drug development. Further complicating binding kinetics, it has been proposed that epilepsy may structurally or functionally modify target sites, for which no biomarker is currently available (Beck, 2007) .
Once a target has been occupied, it should translate into an activation of the cellular processes that are involved in the treatment effect. Important to some of these processes is the second messenger cAMP, which is central to the phosphorylation of ion channels (Misonou et al., 2004) , but is also implicated in epileptogenesis (Zhu et al., 2012) . As these processes take place inside the cell, measuring them is highly invasive in in vivo situations. Alternatively, products that are a direct result of activation and readily cross the BBB, such as (Danhof et al., 2005) .
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miRNA's, could be measured peripherally. For example, miRNA hasmiR-301a-3p was found to correlate to AED resistance in a study of drug-resistant patients, drug-responsive patients, and healthy controls, which may imply its down-stream role after target activation (Wang et al., 2015) . As their patients were already drug-resistant, it cannot be determined if this miRNA was part of the cause or effect of drugresistance. Some evidence exists for the so-called use-dependent blocking effects of AEDs, resulting in a higher AED effect at higher levels of neuronal activity (Beck, 2007) , which may be quantified by an electroencephalogram (EEG), hot glucose PET, or functional magnetic resonance imaging (fMRI).
Type 4 -Physiological Response & Type 5 -Pathophysiological Response
Neuro-inflammation plays a role in epileptogenesis and is a result of seizure activity, making biomarkers that can detect it at an early stage highly valuable in both prevention and treatment. PET can visualise neuro-inflammation by targeting the peripheral benzodiazepine receptor (PBR), otherwise known as translocator protein 18 kDa (TSPO), expressed in many parts of the body, amongst which microglia. In the post-status epilepticus model TSPO peaks around 2 weeks after the initial status epilepticus (Galovic and Koepp, 2016; Bogdanović et al., 2014) . TSPO binding is also increased in foci of pharmaco-resistant patients with focal-onset epilepsy (Gershen et al., 2015) . So far, no quantitative data is available to support setting threshold levels of neuro-inflammation above which anti-inflammatory treatment is indicated. Some miRNAs may be involved in neuro-inflammation by regulating interleukin 1β, cell adhesion molecules, and neuronal growth (Henshall et al., 2016) . How well these miRNAs monitor response in terms of neuro-inflammation (and subsequent neuronal damage) in the clinical setting is as of yet unclear and needs to be further investigated.
Cerebral micro damage due to seizure activity may contribute to disease progression, either due to kindling (i.e. seizures initiate a pathological process of inflammation and dysregulated neuronal growth leading to sustained seizures) or worsening of existing pathophysiology. fMRI characterises brain region activity, active seizure foci and/or inflammation (Olszewska and Costello, 2014) . It can also be coupled to EEG to increase its accuracy of locating epileptic foci and determining the involvement of different brain structures (Gotman and Pittau, 2011) . Diffusion tensor imaging (DTI) traces nerve fibres, thereby illustrating structural connectivity and hierarchical structure, which may be affected both as a cause and as a result of epilepsy (Gong et al., 2009; Iturria-Medina et al., 2008) . BBB disruption occurs during and after seizures, which has a significant impact on cerebral AED concentrations. Dynamic contrast enhanced MRI is able to quantify this BBB disruption, it can track epileptogenesis, and may one day help the physician to determine dose adjustments when a change in cerebral AED exposure is due to changes in BBB permeability or transport.
Brainwaves on an EEG are a direct result of micro processes that are otherwise difficult to measure, allowing insight in the underlying physiology. Standard EEG is non-invasive, does not present a large burden to the patient, and is inexpensive in terms of equipment or application. Interpretation of EEG signals, however, can be time consuming and requires a trained professional with expert knowledge, although advances in machine-based EEG analysis and interpretation are slowly eliminating these issues. A limitation of the use of EEG in the clinic is the reliance on EEG characteristics that were discovered when EEGs could only be analysed with the naked eye, such as highfrequency oscillations, focal slowing, spindles, etc., while these characteristics are not very sensitive to drug effect. Slow adoption of pharmaco-EEG (PEEG) has been attributed to its unreliable translational accuracy, a lack of standardised operating procedures (SOPs), and large inter-individual variability (Jobert et al., 2013) . Methodologies more sensitive to microphysiology and treatment effect are being developed, such as beta wave spectral power correlations with GABAergic inhibition in AED use (Lopes da Silva, 2002).
Type 6 -Clinical Response
The definition of response to AED treatment is ill-defined and may differ between patient, physician, and clinical researcher. Typically, clinical response is a reduction in seizures, but patient and physician may disagree on what would qualify as a satisfactory reduction, and the impact of side effects may be underestimated, possibly leading to poor adherence (Smithson et al., 2012) . In clinical trials, treatment success is defined as a reduction of at least 50% in seizure frequency between baseline and end of the study. This binarisation and the reduction of data leads to a large information loss, and unnecessarily complicates the characterisation of correlations between AED dose, exposure, and response, especially given the large variability between and within individuals (van Dijkman et al., 2016) .
Modelling Perspective
There is a simple adage that states: to measure is to know. Quantification of the intricate mechanisms involved in the disease and its therapy is required to allow optimal prevention, prognosis and treatment. Hence, single biomarkers will not suffice to make informed decisions in the clinic, nor in drug development. Instead, models that integrate biomarkers across the entire range of types ( Fig. 1) are needed. In systems biology and systems pharmacology, problems are considered as part of a network of interactions and complex mechanisms. Systems biology of epilepsy entails the quantification of physiological and pathological processes, roughly corresponding to biomarkers types 0, 4 and 5. Systems pharmacology allows the quantification of physiology-based (PB/)PK/PD, roughly corresponding to biomarker types 1, 2, 3, and 6 (Danhof, 2016) . Fig. 2 , adapted from Sheiner (Sheiner, 1997) , depicts how a physician would determine the individual patient's optimal treatment based on the dimensions of a treatment regimen, its benefits, and the patient's prognostic factors. Whereas this figure may adequately represent diseases with relatively few dimensions, the number of dimensions in epilepsy treatment grows to levels that can no longer be handled without the aid of computer algorithms. Personalised medicine in epilepsy will ultimately require the combination of models from systems biology and systems pharmacology, leading to systems medicine. Epilepsy biomarker literature generally focuses on qualitative biomarkers that categorise patients for diagnosis and prognosis, while systems medicine needs quantitative biomarkers that aid in understanding the systems involved in disease and treatment mechanisms. Using the biomarker classification system, gaps in biomarkers were identified with regard to target occupancy and target activation (Table 1, Fig. 3 ). Such biomarkers characterise how AED Fig. 2 . Example of a simple therapeutic response surface, relating patient prognostic factors and dose regimen to benefit, as net utility of efficacy and toxicity. The best regimen for your patient corresponds to the maximum of the surface on the benefit axis. Adapted with permission from (Sheiner, 1991) .
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exposure at or inside the neuron translates to changes in (patho-) physiology, and thus are essential to determine the cause of pharmacoresistance. Although biomarkers were found that relate to epileptogenesis and prognosis, these did not provide quantitative data allowing the modelling of disease predisposition, generation, and progression. In the following sections we present modelling approaches that may augment the use of existing biomarkers, or reduce the need for biomarkers.
From Dose to Target Site Concentrations
Covariates such as weight, age, sex, comedication, drug binding and cytochrome P450 polymorphisms strongly influence dose to plasma PK and can be pre-emptively adjusted for using PK models, resulting in a more personalised medicine compared to current weight-based dosing algorithms (Knibbe and Danhof, 2011) . A greater challenge is to relate concentrations in plasma to those available for interaction at the target site. Much progress has been made on the PBPK modelling of concentrations in plasma and local brain areas (Westerhout et al., 2012; de Lange and Hammarlund-Udenaes, 2015; Yamamoto et al., 2016) , based on the Mastermind Approach (Fig. 4) (de Lange, 2013) . These models, developed on preclinical data, have been shown, as proof-of-concept, to translate well to humans. Where information was available on human drug concentrations in particular brain compartments (such as lateral ventricle CSF, lumbar spine region, or brain extracellular fluid) this could be adequately predicted by the generic PBPK model after translation of the rat physiological parameter values to the human values. This could replace the need for large invasive studies in humans, although at this stage, it may still require lumbar punctures to measure drug concentrations in CSF for increased accuracy for the individual patient.
From Target Site Concentrations to Target Occupancy & Activation
PET occupancy studies in animals advance the understanding of binding kinetics, which can be translated to humans, assuming that the involved receptor is similar. Such translational approaches led to the discovery of brivaracetam, based on knowledge of SV2A binding kinetics of levetiracetam (Kaminski et al., 2012) . Performing a PET in each patient is infeasible, even if it is restricted to only refractory or pharmacoresistant patients. Instead, transgenic animals with human (mutated) transporter genes could be used to explore how in vitro binding kinetics translate to those in vivo. With sufficient studies, models could be constructed that describe these binding kinetics based on receptor theory (Ploeger et al., 2009) . A promising alternative is the use of PET studies to investigate receptor density and affinity directly (Syvänen et al., 2011) . Binding kinetics either from translational studies or from human studies may then be used in the clinic to predict target occupancy (with subsequent target activation and efficacy) based on the individual's genetic profile, combined with PET to ensure adequate total brain AED exposure. In vitro or in vivo data on receptor density and affinity can be used to inform models on the relation between in vivo binding kinetics, target occupancy and effect profiles (de Witte et al., 2015) .
Epileptogenesis, Ictogenesis & Clinical Outcome
Advances such as next-generation sequencing, epigenetic profiling and proteomics are leading to improved understanding of epileptogenic and ictogenic factors (Rossignol et al., 2014) . Systems biology models based on such knowledge may one day aid in the personalisation of AED therapy by predicting which AED will best interact with or prevent pathological mechanisms (Loeb, 2011) . On a larger scale, modelling of the inhibitory and excitatory processes in the cortex show how their balance breaks down during seizures (Dehghani et al., 2016) . Some neural mass and EEG models are able to describe AED side effects (Vlooswijk et al., 2011) , inter-ictal activity (Caballero-Gaudes et al., 2013) , and seizure activity (Helling et al., 2015) . Due to the increase in understanding of physiology and EEG, PEEG-based personalised medicine may become a reality in the near future (Swatzyna et al., 2015) , and may also prevent AED-related neurotoxicity (Salinsky et al., 2002) .
To avoid the binarisation of treatment effect, seizure count models connect an underlying parameter to efficacy (Plan, 2014) . Recently, the use of stochastic differential equations was proposed to model intraindividual variability in this parameter, allowing further exploration of 
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trends in disease progression (Deng et al., 2016) . The lack in the modelling of AED side effects needs to be addressed, as they have a large impact on treatment cessation and non-adherence. Ideally, models will become available that correlate exposure to both response and side effects, which -as part of a benefit-risk balance-allow patient and physician to make the most informed decision (Bellanti et al., 2015) .
Conclusions
We categorised the available epilepsy biomarkers using a biomarker classification system (Danhof et al., 2005) , and identified gaps (Table 1) . Biomarkers are lacking which provide more overlap between each other in scale (Fig. 3) . Subsequently, we provided examples of advances in systems biology and systems pharmacology that can make better use of -, or even supplant biomarkers. Some of the most pertinent issues in the field of epilepsy pharmacotherapy are: being able to target specific mutations or receptors, to predict disease progression, and to achieve synergy by combining specific AEDs. For this to be achieved, more quantitative biomarker models are needed.
